Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.48 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30446674 | 1.00 | PRMT6 (0.54) | PRMT6P2RY12BMPR1BADORA1P2RX3 | |
| SCHEMBL7032101 | 0.93 | PRMT6 (0.51) | PRMT6P2RY12ADORA1 | |
| SCHEMBL30446733 | 0.93 | PRMT6 (0.51) | PRMT6P2RY12ADORA1 | |
| SCHEMBL8937133 | 0.93 | PRMT6 (0.51) | PRMT6P2RY12ADORA1 | |
| SCHEMBL22206844 | 0.91 | PRMT6 (0.50) | PRMT6P2RY12BMPR1BADORA1P2RX3 | |
| SCHEMBL29479254 | 0.89 | PRMT6 (0.52) | PRMT6P2RY12ADORA1P2RX3P2RX4 | |
| SCHEMBL26653470 | 0.89 | PRMT6 (0.49) | PRMT6P2RY12ADORA1 | |
| SCHEMBL19128447 | 0.89 | PRMT6 (0.51) | PRMT6P2RY12ADORA1 | |
| SCHEMBL19128052 | 0.89 | PRMT6 (0.51) | PRMT6P2RY12ADORA1 | |
| SCHEMBL13020575 | 0.89 | MEN1 (0.50) | PRMT6P2RY12ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | VICTORIA LINK LIMITED (NZ) | 2022-12-06 | — | — | US | disclosed |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | VICTORIA LINK LTD (NZ) | 2021-07-08 | — | — | US | disclosed |
| CN-111434671-A | Liver specificity AMPK agonist and preparation method and application thereof | 凯思凯迪（上海）医药科技有限公司 | 2020-07-21 | — | — | CN | disclosed |
| WO-2020143800-A1 | LIVER-SPECIFIC AMPK AGONIST, PREPARATION METHOD THEREFOR AND USES THEREOF | 凯思凯迪（上海）医药科技有限公司 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | DNMT1, DNMT3A, DNMT3B | PRMT6 28/4885P2RY12 4803/4885BMPR1B 3627/4885 |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | DNMT1, DNMT3B, DNMT3A | PRMT6 27/4885P2RY12 4771/4885BMPR1B 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.